Active Not Recruiting PHASE1 INTERVENTIONAL 15-arm NCT03821935

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Locally Advanced or Metastatic Solid Tumors

Sponsor: AbbVie

Conditions Advanced Solid Tumors Cancer

Interventions Budigalimab Livmoniplimab

Updated 38 times since 2019 Last updated: May 21, 2025 Started: Feb 21, 2019 Primary completion: Jun 30, 2027 Completion: Jun 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Solid Tumors Cancer, this trial is ongoing. The trial is conducted by AbbVie and has accumulated 38 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

38 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE1
Jun 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
May 2025 — Jun 2025 [monthly]

Recruiting PHASE1
Apr 2025 — May 2025 [monthly]

Recruiting PHASE1
Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE1

▶ Show 33 earlier versions

Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE1
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE1
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE1
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE1
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE1
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
May 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Apr 2024 — May 2024 [monthly]

Recruiting PHASE1
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE1
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE1
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE1
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE1
Aug 2023 — Nov 2023 [monthly]

Recruiting PHASE1
Jun 2023 — Aug 2023 [monthly]

Recruiting PHASE1
Mar 2023 — Jun 2023 [monthly]

Recruiting PHASE1
Jan 2023 — Mar 2023 [monthly]

Recruiting PHASE1
Sep 2022 — Jan 2023 [monthly]

Recruiting PHASE1
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE1
Feb 2022 — Jul 2022 [monthly]

Recruiting PHASE1
Dec 2021 — Feb 2022 [monthly]

Recruiting PHASE1
Nov 2021 — Dec 2021 [monthly]

Recruiting PHASE1
Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE1
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE1
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE1
Jan 2021 — Jun 2021 [monthly]

Recruiting PHASE1
Jul 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Dec 2019 — Jul 2020 [monthly]

Recruiting PHASE1
Oct 2019 — Dec 2019 [monthly]

Recruiting PHASE1
Jun 2019 — Oct 2019 [monthly]

Recruiting PHASE1
Apr 2019 — Jun 2019 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Feb 2019 — Apr 2019 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akashi-shi, Japan , Ann Arbor, United States , Barcelona, Spain , Billings, United States , Brussels, Belgium , Camperdown, Australia , Celebration, United States , Chuo-ku, Japan , Clermont-Ferrand, France , Columbus, United States and 43 more locations